Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

Inclusion Criteria:

• Body mass index (BMI) must be ≥19 to <45 kg/m^2 at the Screening Visit

• Participant must have uncontrolled hypertension defined as meeting both of thefollowing criteria:

• The participant has a resting seated trough cuff SBP ≥140 mm Hg at theScreening Visit (Visit 1), and at the start (Visit 2) and end (Visit 3) of theRun-In Period

• The participant is taking 2 or more antihypertensive medications that have beentitrated upward as tolerated to hypertension target doses per local SoC andhave been stable (i.e., without any dose adjustments) from 4 weeks before theScreening Visit (Visit 1) through the end of the Run-In Period (Visit 3)

• The participant must have Stage 3b (eGFR [EPI] ≥30 and ≤44 mL/min/1.73 m^2) or Stage 4 (eGFR [EPI] ≥15 and <30 mL/min/1.73 m^2) CKD.

Exclusion Criteria:

• Participant has a resting seated trough cuff SBP ≥180 mm Hg at the Screening Visit (Visit 1) or at the start (Visit 2) or end (Visit 3) of the Run-In Period

• Participant has a serum potassium level >4.8 mmol/L during the Screening or Run-InPeriods

• Participant has had a serum potassium level >5.6 mmol/L within 2 weeks before theScreening Visit (Visit 1)

• Participant has been hospitalized for hyperkalemia within the 3 months before theRandomization Visit (Visit 3)

• Participant was not compliant with taking placebo during the Run-in Period orparticipant was not compliant with background antihypertensive medications duringthe Run-in Period as assessed at the Randomization Visit (Visit 3)

• Participant has taken an mineralocorticoid receptor antagonist (MRA), apotassium-sparing diuretic, or chronic potassium supplements during the 4 weeksbefore the Screening Visit (Visit 1)

• Participant has taken potassium binders for the treatment of hyperkalemia during the 3 months before the Screening Visit (Visit 1)

• Participant has taken a strong cytochrome P450 (CYP) CYP3A4 inducer or strong CYP3A4inhibitor during the 7 days before the Randomization Visit (Visit 3)

• Participant has taken a prohibited traditional Chinese medication during the 28 daysprior to Screening Visit (Visit 1).

• Participant was administered any other investigational product within 4 weeks or 5half-lives (whichever is longer) prior to the Screening Visit (Visit 1).